https://allsci.com/news/clinical-trials/caldera-taps-reverse-merger-to-advance-tl1a-x-il-23-bispecific/ AllScien 2026-07-29T17:17:16.972374Z Caldera taps reverse merger to advance TL1A × IL-23 bispecific https://allsci.com/news/venture-financing/adjuvia-raises-usd-8m-for-preclinical-stage-mitochondrial-therapy/ AllScien 2026-07-29T17:04:21.481730Z Adjuvia raises USD 8m for preclinical-stage mitochondrial therapy https://allsci.com/news/licensing-and-partnerships/abcellera-adds-vertex-as-latest-tce-platform-partner-in-autoimmune-disease/ AllScien 2026-07-29T16:51:36.452179Z AbCellera adds Vertex as latest TCE platform partner in autoimmune disease https://allsci.com/news/licensing-and-partnerships/qnovia-bets-on-antimicrobial-peptides-with-exclusive-uva-deal/ AllScien 2026-07-29T16:27:15.812498Z Qnovia bets on antimicrobial peptides with exclusive UVA deal https://allsci.com/news/funding/lb-pharma-raises-usd-150m-to-expand-lb-102-zinto-three-neuropsychiatric-indications/ AllScien 2026-07-29T16:15:58.867734Z LB Pharma raises USD 150m to expand LB-102 zinto three neuropsychiatric indications https://allsci.com/news/clinical-trials/hansohs-b7-h3-adc-set-for-china-filing-after-hitting-phase-iii-endpoint-in-osteosarcoma/ AllScien 2026-07-29T15:59:41.622724Z GSK/Hansoh's B7-H3 ADC set for China filing after hitting Phase III endpoint in osteosarcoma https://allsci.com/news/funding/shape-therapeutics-secures-funding-to-advance-one-time-gene-therapy-for-parkinsons-disease/ AllScien 2026-07-29T13:40:59.980831Z Shape Therapeutics secures funding to advance one-time gene therapy for Parkinson's disease. https://allsci.com/news/clinical-trials/gsk-accelerates-20-plus-phase-iii-starts-through-gbp-1-9b-savings-program/ AllScien 2026-07-29T13:27:47.985456Z GSK accelerates 20-plus Phase III starts through GBP 1.9b savings program https://allsci.com/news/funding/basilea-secures-usd-30m-barda-tranche-to-advance-fosmanogepix-phase-iii-trials/ AllScien 2026-07-29T11:15:57.466568Z Basilea secures USD 30m BARDA tranche to advance fosmanogepix Phase III trials https://allsci.com/news/regulatory/fda-clears-registrational-phase-ii-path-for-cullinans-cln-049-in-relapsed-refractory-aml/ AllScien 2026-07-29T09:08:33.994742Z FDA clears registrational Phase II path for Cullinan's CLN-049 in relapsed/refractory AML https://allsci.com/news/clinical-trials/ateas-hepatitis-c-combination-meets-non-inferiority-bar-clears-path-to-regulatory-filing/ AllScien 2026-07-29T09:05:26.168035Z Atea's hepatitis C combination meets non-inferiority bar, clears path to regulatory filing https://allsci.com/news/pharma/core-launches-with-a-portfolio-licensed-from-eisai-plus-usd-21m-in-financing/ AllScien 2026-07-29T08:47:31.994194Z CORE launches with a portfolio licensed from Eisai plus USD 21m in financing https://allsci.com/news/regulatory/fda-adcom-briefing-raises-broad-efficacy-concerns-over-replimunes-melanoma-bla/ AllScien 2026-07-29T08:40:23.917753Z FDA AdCom briefing raises broad efficacy concerns over Replimune's melanoma BLA https://allsci.com/news/finance/claris-bio-raises-usd-118m-to-advance-first-ever-pharmacologic-therapy-for-limbal-stem-cell-deficiency/ AllScien 2026-07-28T15:48:38.514151Z Claris Bio raises USD 118m to advance first-ever pharmacologic therapy for limbal stem cell deficiency https://allsci.com/news/clinical-trials/altimmunes-pemvidutide-sees-clear-path-forward-in-alcohol-use-disorder-after-strong-phase-ii/ AllScien 2026-07-28T14:32:07.001312Z Altimmune's pemvidutide sees clear path forward in alcohol use disorder after strong Phase II https://allsci.com/news/clinical-trials/treeline-opens-phase-i-trial-of-tln-499-plus-venetoclax-in-bcl-2-dependent-solid-tumors/ AllScien 2026-07-28T13:05:30.938733Z Treeline opens Phase I trial of TLN-499 plus venetoclax in BCL-2-dependent solid tumors https://allsci.com/news/research/promatix-advances-egfr-x-epha2-cis-bispecific-adc-with-innovate-uk-funding/ AllScien 2026-07-28T12:20:15.899451Z Promatix advances EGFR × EphA2 cis-bispecific ADC with Innovate UK funding https://allsci.com/news/clinical-trials/promis-reports-no-aria-e-in-blinded-six-month-alzheimers-trial-update/ AllScien 2026-07-28T12:13:41.264501Z ProMIS reports no ARIA-E in blinded six-month Alzheimer's trial update https://allsci.com/news/regulatory/abelzeta-wins-fda-clearance-for-registrational-phase-ii-study-of-lupus-nephritis-car-t/ AllScien 2026-07-28T11:47:28.900269Z AbelZeta wins FDA clearance for registrational Phase II study of lupus nephritis CAR-T https://allsci.com/news/clinical-trials/yarrow-completes-reverse-merger-with-vyne-enters-phase-ii-with-tshr-antibody/ AllScien 2026-07-28T10:02:28.120913Z Yarrow completes reverse merger with VYNE, enters Phase II with TSHR antibody https://allsci.com/news/pharma/harbour-bio-pairs-harbour-mice-platform-with-sinopharm-to-develop-biologics-across-oncology-and-inflammation/ AllScien 2026-07-28T09:53:40.178667Z Harbour Bio pairs Harbour Mice platform with Sinopharm to develop biologics across oncology and inflammation https://allsci.com/news/clinical-trials/viivs-two-drug-dovato-matches-three-drug-biktarvy-in-first-head-to-head-hiv-trial/ AllScien 2026-07-28T08:24:47.464666Z ViiV's two-drug Dovato matches three-drug Biktarvy in first head-to-head HIV trial https://allsci.com/news/clinical-trials/astrazenecas-sonesitatug-vedotin-delivers-first-phase-iii-os-win-for-cldn18-2-adc-in-gastric-cancer/ AllScien 2026-07-28T08:21:12.841415Z AstraZeneca's sonesitatug vedotin delivers first Phase III OS win for CLDN18.2 ADC in gastric cancer https://allsci.com/news/clinical-trials/maplights-m1-m4-agonist-aces-phase-ii-schizophrenia-trial/ AllScien 2026-07-28T07:43:47.649899Z MapLight's M1/M4 agonist aces Phase II schizophrenia trial